Oxaliplatin responses in colorectal cancer cells are modulated by CHK2 kinase inhibitors.
AffiliationClinical and Experimental Pharmacology Group, Paterson Institute for Cancer Research, University of Manchester, Manchester, UK.
MetadataShow full item record
AbstractBACKGROUND AND PURPOSE: Checkpoint kinase 2 (CHK2) is activated by DNA damage and can contribute to p53 stabilization, modulating growth arrest and/or apoptosis. We investigated the contribution of CHK2 to oxaliplatin-mediated toxicity in a colorectal cancer model. EXPERIMENTAL APPROACH: We evaluated the ability of CHK2 small molecule inhibitors to potentiate oxaliplatin-induced toxicity. The role of CHK2 in oxaliplatin-induced apoptosis was investigated in HCT116 cells that were wild-type (WT) or KO for CHK2. Small molecule inhibitors of CHK2 were used in combination studies with oxaliplatin in this cell model. KEY RESULTS: In oxaliplatin-treated CHK2 KO cells, accelerated apoptosis was accompanied by attenuated p53 stabilization and p21(WAF-1) up-regulation correlating with increased Bax expression, cytochrome c release and elevated caspase activity. The higher levels of apoptosis in CHK2 KO cells were restored to control (WT) levels when CHK2 was re-introduced. This 'uncoupling' of p53 stabilization and Bax up-regulation in CHK2 KO cells suggested oxaliplatin-induced apoptosis was due to a p53-independent response. Combination studies revealed that CHK2 inhibitor II or debromohymenialdisine antagonized the responses to oxaliplatin. This inhibitory effect correlated with decreases in apoptosis, p53 stabilization and DNA inter-strand cross-link formation, and was dependent on the presence (but not activity) of CHK2. CONCLUSIONS AND IMPLICATIONS: Combinations of CHK2 inhibitors with oxaliplatin should further sensitize cells to oxaliplatin treatment. However, these inhibitors produced an antagonistic effect on the response to oxaliplatin, which was reversed on the re-introduction of CHK2. These observations may have implications for the use of oxaliplatin in colorectal cancer therapy in combination with therapies targeting CHK2.
CitationOxaliplatin responses in colorectal cancer cells are modulated by CHK2 kinase inhibitors. 2010, 159 (6):1326-38 Br. J. Pharmacol.
JournalBritish Journal of Pharmacology
- UCN-01 inhibits p53 up-regulation and abrogates gamma-radiation-induced G(2)-M checkpoint independently of p53 by targeting both of the checkpoint kinases, Chk2 and Chk1.
- Authors: Yu Q, La Rose J, Zhang H, Takemura H, Kohn KW, Pommier Y
- Issue date: 2002 Oct 15
- Oxaliplatin-induced gamma-H2AX activation via both p53-dependent and -independent pathways but is not associated with cell cycle arrest in human colorectal cancer cells.
- Authors: Chiu SJ, Lee YJ, Hsu TS, Chen WS
- Issue date: 2009 Dec 10
- Regulation of gamma-H2AX and securin contribute to apoptosis by oxaliplatin via a p38 mitogen-activated protein kinase-dependent pathway in human colorectal cancer cells.
- Authors: Chiu SJ, Chao JI, Lee YJ, Hsu TS
- Issue date: 2008 Jun 30
- Molecular mechanisms of action and prediction of response to oxaliplatin in colorectal cancer cells.
- Authors: Arango D, Wilson AJ, Shi Q, Corner GA, Arañes MJ, Nicholas C, Lesser M, Mariadason JM, Augenlicht LH
- Issue date: 2004 Nov 29
- Enhanced oxaliplatin-induced apoptosis following antisense Bcl-xl down-regulation is p53 and Bax dependent: Genetic evidence for specificity of the antisense effect.
- Authors: Hayward RL, Macpherson JS, Cummings J, Monia BP, Smyth JF, Jodrell DI
- Issue date: 2004 Feb